Phio Pharmaceuticals (PHIO) Non-Current Deferred Tax Liability (2020 - 2024)
Phio Pharmaceuticals' (PHIO) quarterly Non-Current Deferred Tax Liability came in at $13000.0 in Q4 2024, down 69.77% on a QoQ basis from $43000.0 in Q4 2022.
Phio Pharmaceuticals (PHIO) Non-Current Deferred Tax Liability (2020 - 2024) Analysis & Trends
Phio Pharmaceuticals (PHIO) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $13000.0 in Q4 2024.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $13000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $13000.0 (changed N/A YoY) and the FY2024 annual result came in at $13000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability declined to $13000.0 in Q4 2024, from $43000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $108000.0 in Q4 2020 to a low of $13000.0 in Q4 2024.
- A 4-year average of $60000.0 and a median of $59500.0 in 2021 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2021 — Non-Current Deferred Tax Liability dropped 29.63% — and 2022, when it slumped 43.42%.
- Tracing PHIO's Non-Current Deferred Tax Liability over 4 years: stood at $108000.0 in 2020, then retreated by 29.63% to $76000.0 in 2021, then tumbled by 43.42% to $43000.0 in 2022, then sank by 69.77% to $13000.0 in 2024.
- The last three Non-Current Deferred Tax Liability figures came in at $13000.0 (Q4 2024), $43000.0 (Q4 2022), and $76000.0 (Q4 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Phio Pharmaceuticals | 13.77 Mn | 13.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Dec 31, 2022 | 43,000.00 |
| Dec 31, 2022 | 43,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Dec 31, 2021 | 76,000.00 |
| Dec 31, 2020 | 108,000.00 |
| Dec 31, 2020 | 108,000.00 |